The clinical question remains as to whether stress is a trigger—or at least an exacerbating factor—in psoriasis and if so, how this should influence treatment approaches.
Future randomized clinical trials should report absolute Psoriasis Area and Severity Index at follow-up, in order to improve the transferability between trial data and real-world data.
According to results from the ECLIPSE trial, treatment with guselkumab was found to be superior to secukinumab in adult patients with moderate-to-severe plaque psoriasis based on 90% or better improvement in patients’ Psoriasis Area and Severity Index score compared to baseline (PASI 90 response).
The first evaluation of the effects of brodalumab treatment in patients with and without obesity with psoriasis found no difference in safety or efficacy between the two patient populations.
A clinical guideline for the use of phototherapy for the care and management of adult patients with psoriasis developed by the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) has been published.
In this first report of a head-to-head trial comparing risankizumab and adalimumab, the former agent was found to demonstrate greater efficacy in patients with moderate to severe plaque psoriasis.
